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Metabotropic glutamate (Glu) receptors (mGluRs) and GABAB receptors are highly
expressed at presynaptic sites. To verify the possibility that the two classes of
metabotropic receptors contribute to axon terminals heterogeneity, we studied the
localization of mGluR1α, mGluR5, mGluR2/3, mGluR7, and GABAB1 in VGLUT1-,
VGLUT2-, and VGAT- positive terminals in the cerebral cortex of adult rats.
VGLUT1-positive puncta expressed mGluR1α (∼5%), mGluR5 (∼6%), mGluR2/3
(∼22%), mGluR7 (∼17%), and GABAB1 (∼40%); VGLUT2-positive terminals expressed
mGluR1α (∼10%), mGluR5 (∼11%), mGluR2/3 (∼20%), mGluR7 (∼28%), and GABAB1
(∼25%); whereas VGAT-positive puncta expressed mGluR1α (∼27%), mGluR5 (∼24%),
mGluR2/3 (∼38%), mGluR7 (∼31%), and GABAB1 (∼19%). Control experiments ruled
out the possibility that postsynaptic mGluRs and GABAB1 might have significantly
biased our results. We also performed functional assays in synaptosomal preparations,
and showed that all agonists modify Glu and GABA levels, which return to baseline
upon exposure to antagonists. Overall, these findings indicate that mGluR1α, mGluR5,
mGluR2/3, mGluR7, and GABAB1 expression differ significantly between glutamatergic
and GABAergic axon terminals, and that the robust expression of heteroreceptors
may contribute to the homeostatic regulation of the balance between excitation and
inhibition.
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Introduction
Presynaptic mechanisms aﬀecting neurotransmitter release
play a key role in modulating synaptic strength and plasticity
(Atwood and Karunanithi, 2002); they may be associated to
molecular heterogeneity of axon terminals (Staple et al., 2000).
Following the demonstration that more than 2,000 genes are
diﬀerentially expressed in glutamatergic and GABAergic
neurons (Sugino et al., 2006), we investigated whether
glutamatergic and GABAergic release machineries could be
diﬀerentiated on the basis of the proteins they express, and
showed that in cerebral cortex the expression pattern of several
presynaptic proteins involved in transmitter release (including
synapsins, synaptophysins, synaptosomal-associated proteins,
synaptogyrins, synaptobrevin/vesicle-associated membrane
proteins, syntaxins, synaptotagmins, synaptic vesicle proteins,
and Rab3) varies both between glutamatergic and GABAergic
terminals and between VGLUT1+ and VGLUT2+ glutamatergic
terminals (Bragina et al., 2007, 2010, 2011).
Metabotropic glutamate (Glu) receptors (mGluRs) and
GABAB modulates neuronal excitability, transmitter release,
and synaptic plasticity (Bowery et al., 1980; Herrero et al.,
1992; Pin and Duvoisin, 1995). mGluRs consist of at least
eight subtypes classiﬁed into three groups: group I receptors
(mGluR1 and 5), coupled to the Gq signal pathway, are
predominantly postsynaptic, and generally potentiate neuronal
excitability; group II (mGluR2 and 3) and group III receptors
(mGluR 4, 6, 7, and 8), linked to Gi/Go and thus cAMP
inhibitors, are predominantly presynaptic and usually decrease
excitability (Shigemoto et al., 1997; Gereau and Swanson, 2008).
Notwithstanding the value of this general scheme, it is worth
noting that the localization of mGluRs is more complex. Indeed,
besides mGluR2/3 and mGluR7, mGluR1α and mGluR5 are also
expressed presynaptically at asymmetric and symmetric synapses
in diﬀerent brain regions, including cerebral cortex (Romano
et al., 1995; Bradley et al., 1996; Petralia et al., 1996; Lujan et al.,
1997; Shigemoto et al., 1997; Kinoshita et al., 1998; Tamaru et al.,
2001; Dalezios et al., 2002; Muly et al., 2003; Paquet and Smith,
2003; Somogyi et al., 2003; Rodrigues et al., 2005; Musante et al.,
2008; Giribaldi et al., 2013), where they also modulate positively
or negatively glutamate and GABA release (Herrero et al., 1992;
Battaglia et al., 1997; Li et al., 2008; Musante et al., 2008; Summa
et al., 2013).
GABAB are coupled to Gi/Go proteins and decrease neuronal
excitability in both pre- and postsynaptic elements; they exist
as heterodimers (of GABAB1 and GABAB2 subunits) which
yield functional receptors (Kaupmann et al., 1998; White
et al., 1998; Gonchar et al., 2001; Lopez-Bendito et al., 2002;
Tabata et al., 2004). GABAB1 is expressed presynaptically
in several brain regions (Kulik et al., 2002, 2003; Lujan
et al., 2004; McDonald et al., 2004; Lacey et al., 2005; Lujan
and Shigemoto, 2006), including the cerebral cortex, where
it is localized at both symmetric and asymmetric synapses
(Gonchar et al., 2001; Lopez-Bendito et al., 2002). One major
function of presynaptic GABAB receptors is modulation of
neurotransmitter release, as they inhibit the release of both
glutamate and GABA in diﬀerent regions of the CNS, including
cerebral cortex (Bowery et al., 1980; Bonanno and Raiteri,
1993).
The widespread localization of mGluRs and GABAB
at presynaptic sites raises the possibility that both classes
of metabotropic receptors contribute to axon terminals
heterogeneity. To verify this hypothesis, we studied the
localization of mGluR1α, mGluR5, mGluR2/3, mGluR7, and
GABAB1 in VGLUT1+, VGLUT2+, and VGAT+1 terminals in
the cerebral cortex of adult rats. We report that the expression of
these receptors diﬀers signiﬁcantly between glutamatergic
and GABAergic axon terminals, and that expression of
heteroreceptors is greater than expected. We also performed
functional assays in synaptosomal preparations, and showed
that all agonists modify Glu and GABA levels, which return to
baseline upon antagonists administration.
Materials and Methods
Animals and Tissue Preparation
Adult male Sprague–Dawley rats (190–220 g; Charles River,
Milan, Italy) were used. All experiments were carried out in
accordance with the European Community Council Directive
dated November 24, 1986 (86/609 EEC), and were approved
by the local authority veterinary service (CESA, Comitato Etico
per la Sperimentazione Animale; Università Politecnica delle
Marche). Animals were kept under a dark–light cycle of 12 h and
permitted food and water ad libitum.
For synaptosome puriﬁcation, release experiments, and
western blotting, rats were euthanized and brains rapidly
removed. Homogenization of neocortex, membrane preparation,
protein determination, SDS-PAGE analysis, and immunoblotting
were performed as described (Bragina et al., 2006). Precast gels
(Tris-HCl; BioRad, Hercules, CA, USA) were used at 4–20%
polyacrylamide concentration for metabotropic receptors (15 μg
total proteins) and at 7.5% for the vesicular transporters (10 μg
total proteins).
For immunocytochemical studies, rats were anesthetized with
chloral hydrate (300 mg/kg i.p.) and perfused through the
ascending aorta with saline followed by 4% paraformaldehyde in
0.1 M phosphate buﬀer (PB; pH 7.4). Brains were post-ﬁxed for
1 day at 4◦C in the same ﬁxative, cut with a Vibratome into 30μm
thick sections, and processed.
Antibodies
The primary antibodies used are listed in Table 1. Western blots
were performed to verify antibodies speciﬁcity; nitrocellulose
ﬁlters were probed with antibodies to VGLUT1, VGLUT2,
VGAT, mGluR1α, mGluR5, mGluR2/3, mGluR7, and GABAB1
at the dilutions reported in Table 1. After exposure to
the appropriate peroxidase-conjugated antibodies (Vector;
Burlingame, CA, USA), immunoreactive bands were visualized
1The vesicular transporter described by McIntire et al. (1997) and Sagné et al.
(1997) does transport both GABA and glycine (Wojcik et al., 2006), and is termed
either VGAT (McIntire et al., 1997) or VIAAT (Sagné et al., 1997). Here, in line with
its widespread usage and with the more prominent role of GABA in neocortex, we
follow the terminology of McIntire et al. (1997).
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TABLE 1 | Primary antibodies.
Host◦ Dilution∗ Source Characterization
VGAT M 1:50 (IF)
1:500 (WB)
Synaptic System/131011 Bogen et al. (2006), Tafoya et al. (2006)
VGLUT1 GP 1:1000 (IF)
1:2000 (WB)
Millipore/AB5905 Melone et al. (2005)
VGLUT2 GP 1:1000 (IF)
1:2000 (WB)
Millipore/AB5907 Cubelos et al. (2005), Liu et al. (2005)
mGluR1α R 1:250 (IF and WB) Millipore/AB1551 Muly et al. (2003)
mGluR5 R 1:250 (IF and WB) Millipore/AB5675 Muly et al. (2003)
mGluR2/3 R 1:50 (IF)
1:250 (WB)
Millipore/AB1553 Petralia et al. (1996)
mGluR7 R 1:250 (IF and WB) Millipore/07-239 Pinheiro et al. (2007)
GABAB1 R 1:250 (IF and WB) Dr. A. Kulik, Freiburg (Germany) Kulik et al. (2002)
◦GP, guinea pig; M, mouse; R, rabbit; ∗ IF, immunofluorescence; WB, western blotting.
by BioRad Chemidoc and Quantity One software (BioRad,
Hemel Hempstead, UK) using the SuperSignal West Pico
(Rockford, IL, USA) chemiluminescent substrate.
Co-localization Studies
Sections were incubated for 1 h in normal goat serum (NGS;
10% in PB with 0.2% Triton X-100), and then overnight
at room temperature in a solution containing a mixture
of the primary antibodies. The next day, sections were
incubated in 10% NGS (30 min), and then for 90 min in a
mixture of the appropriate secondary ﬂuorescent antibodies.
For the VGLUT1 and VGLUT2 series, we used ﬂuorescein
isothiocyanate-conjugated goat anti-guinea-pig IgG (FI-7000,
Vector; Burlingame, CA, USA) for the vesicular transporters
(1:100) and tetramethylrhodamine isothiocyanate-conjugated
goat anti-rabbit IgG (T-2769, Molecular Probes; Poort Gebouw,
The Netherlands) for the metabotropic receptors (1:100);
for the VGAT series, we used ﬂuorescein goat anti-mouse
IgG (F-2761, Molecular probes) for the vesicular transporter
(1:100) and tetramethylrhodamine isothiocyanate-conjugated
goat anti-rabbit IgG (T-2769, Molecular Probes; Poort Gebouw,
The Netherlands) for the metabotropic receptors (1:100).
Sections were then mounted, air-dried, and coverslipped using
Vectashield mounting medium (H-1000; Vector). Double-
labeled sections were examined using a Leica (TCS SP2)
confocal laser microscope equipped with an argon (488 nm)
and a helium/neon (543 nm) laser for excitation of ﬂuorescein
isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate
(TRITC), respectively. Green and red immunoﬂuorescence were
imaged sequentially and emissions separated with 515/30 nm
band pass (FITC) and 570 nm long pass (TRITC) ﬁlters. Control
experiments with single-labeled sections and sections incubated
either with two primary and one secondary antibody, or with one
primary and two secondary antibodies revealed no appreciable
FITC/TRITC bleed-through or antibody cross-reactivity.
Images of experimental series were collected from a region of
the parietal cortex characterized by a conspicuous layer IV, with
intermingled dysgranular regions, densely packed layers II and
III, and a relatively cell-free layer Va. This area corresponds to the
ﬁrst somatic sensory cortex (SI), as identiﬁed also byWoolsey and
LeMessurier (1948),Welker (1971), Zilles et al. (1980), Donoghue
and Wise (1982). Images were acquired from randomly selected
subﬁelds in layers II–VI (at least 4–6/layer; 2–4 sections/animal;
10 rats). Layer I was not sampled because it hardly contains
VGAT+ puncta (Chaudhry et al., 1998; Minelli et al., 2003).
Images were acquired using a 63× oil immersion lens (numerical
aperture 1.4; pinhole 1.0 and image size 1,024 × 1,024 pixels,
yielding a pixel size of 0.06 μm) from a plane in which the
resolution of both stains was optimal and always between 1.3
and 1.8 μm from the surface. To improve the signal/noise ratio,
10 frames/image were averaged.
Quantitative analysis was performed in ∼8,000 randomly
selected subﬁelds measuring about 25 × 25 μm from the
1,024 × 1,024 pixel images. In order to minimize the
fusion of puncta, the contrast of each image was adjusted
manually within the maximum range of levels for each color
channel. Analysis of contrast adjustment (not shown) showed
that gain/contrast changes within the spectrum used did not
alter signiﬁcantly the percentage of puncta. Then, without
reducing the image resolution, the images were binarized and
processed by watershed ﬁlter using ImageJ software (bfd).
Next, each channel was examined separately to identify and
count with ImageJ immunopositive puncta; the two channels
were then merged and the number of co-localizing puncta
was counted manually. Puncta were considered double-labeled
when overlap was virtually complete or when a given punctum
was entirely included in the other. Moreover, we analyzed
∼2,000 randomly selected subﬁeld (25 × 25 μm) from the
1,024 × 1,024 pixel images acquired in molecular layer
of cerebellum and ventrobasal nucleus (10–20/section; 2–
4section/animal; 2 animals).
In addition, we compared our manual method with a
computerized overlap analysis that deﬁnes two objects as co-
localized if the centre of mass of one falls within the area
of the other (Lachmanovich et al., 2003). To this end, we
analyzed about half of all double-labeled sections studied
here with the overlap method included in JACoP toolbox
of ImageJ (Bolte and Cordelieres, 2006), and found that the
percentage of co-localization obtained with the twomethods were
comparable.
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Synaptosomes Purification
Synaptosomes were prepared from rat neocortex with a protocol
modiﬁed by Dunkley et al. (1986) and Stigliani et al. (2006).
Brieﬂy, rats were sacriﬁced and brain were rapidly removed.
Parietal cortices were homogenized in 10 volume of Tris buﬀer
(4◦C; pH 7.4) containing 0.32 M sucrose, EDTA 1 mM and
protease inhibitors (Complete EDTA-free; Roche Molecular
Biochemicals, Indianapolis, IN, USA), and centrifuged at 1,000 g
for 5 min to remove nuclei and cellular debris. Subsequently,
supernatant was centrifuged at 9,200 g for 10 min. Synaptosomal
fraction were puriﬁed by centrifugation a 33,000 g using
Percoll-sucrose density gradient (2–6–10–20%) for 5 min. The
synaptosomal fraction (10–20%) Percol interface was washed by
centrifugation at 20,000 g for 15 min at 4◦C, and resuspended in
fresh physiologic medium having the following composition (in
mM): 140 NaCl, 3 KCl, 1.2MgSO4, 1.2 NaH2PO4, 5 NaHCO3, 1.2
CaCl2; 10 Hepes, and 10 glucose (pH 7.4) for release experiments.
Release Experiments
Synaptosomes (from 32 rats) were incubated at 37◦C for 15 min;
aliquots of synaptosomal suspension (150 μg) were layered on
microporous ﬁlters placed at the bottom of a set of parallel
superfusion chambers maintained at 37◦C (Superfusion System;
Ugo Basile, Comerio, Italy; (Raiteri et al., 1984). Superfusion
was started with standard medium at a rate of 0.5 ml/min and
continued for 48 min. In the experiments aimed at measuring
basal Glu and GABA release, after 36 min of superfusion
to equilibrate the system, fractions were collected according
to the following scheme: four 3-min samples (t = 36–39,
basal release; t = 39–42, t = 42–45, and t = 45–48, drug-
induced release). The mGluR1 and mGluR5 agonist 3,5-DHPG
(30 μM) was introduced at t = 39, after the ﬁrst sample
was collected. When appropriate, the selective mGluR1 and
mGluR5 antagonists LY367385 (1 μM) and MPEP (1 μM),
respectively, were introduced at t = 30 and maintained until
the end of the experiment. Drug eﬀects were evaluated by
comparing the amount of endogenous Glu or GABA (pmol/mg
synaptosomal protein) in the fourth sample collected (in which
maximum eﬀect of 3,5-DHPG was generally reached) with
the content in the ﬁrst sample (basal eﬄux). In experiments
aimed at measuring the stimulus-evoked Glu and GABA release,
after 36 min of superfusion to equilibrate the system, fractions
were collected according to the following scheme: two 3-min
samples (t = 36–39 min and t = 45–48 min; basal outﬂow)
before and after one 6-min sample (t = 39–45 min; stimulus-
evoked release). A 90-s period of stimulation was applied at
t = 39 min, after the collection of the ﬁrst sample. Stimulation
of synaptosomes was performed by 15 mM KCl, substituting
for equimolar concentration of NaCl. The mGluR2 and mGluR3
agonist LY379268 (100 nM), the mGluR7 agonist AMN082
(100 nM) or the GABAB receptor agonist (-)baclofen (10 μM)
was introduced at t = 39 min concomitantly to the KCl
pulse. When appropriate, the selective mGluR2 and mGluR3
antagonist LY341495 (100 nM), the selective mGluR7 antagonist
MMPIP (10 nM) or the selective GABAB antagonist CGP52432
(1 μM) was introduced at t = 30 min and maintained until
the end of the experiment. The stimulus-evoked overﬂow
was estimated by subtracting the endogenous neurotransmitter
release content of the two 3-min fractions (basal outﬂow) from
the endogenous neurotransmitter amount collected in the 6-min
fraction (stimulus-evoked overﬂow).
Endogenous Glu and GABA content in the samples collected
was measured by high performance liquid chromatography
following pre-column derivatization with o-phthalaldehyde and
gradient separation on a C18 reverse-phase chromatographic
column (10 mm × 4.6 mm, 3 μm; at 30◦C; Chrompack,
Middleburg, The Netherlands) coupled with ﬂuorometric
detection (excitation wavelength 350 nm; emission wavelength
450 nm). Homoserine was used as an internal standard (Bonanno
et al., 2005). The following buﬀers were used: solvent A, 0.1 M
sodium acetate (pH 5.8)/methanol 80:20; solvent B, 0.1M sodium
acetate (pH 5.8)/methanol, 20:80; solvent C, sodium acetate (pH
6.0)/methanol, 80:20. The gradient program was as follows: 100%
C for 4 min from the initiation of the program; 90% A and 10% B
in 1 min; 42% A and 58% B in 14 min; 100% B in 1 min; isocratic
ﬂow 2 min; 100% C in 3 min; ﬂow rate 0.9 mL/min. Amino
acid release content was expressed as picomoles per milligram of
synaptosomal protein.
All chemicals were of the purest analytical grade. (s)-3,5-
Dihydroxyphenylglycine ((s)3,5-DHPG, ab120007), 2-Methyl-6-
(phenylethynyl)pyridine hydrochloride (MPEP hydrochloride,
ab120008), (S)-(+)-α-Amino-4-carboxy-2-methylbenzeneacetic
FIGURE 1 | VGLUT1, VGLUT2, VGAT, mGluR1α, mGluR5, mGluR2/3, mGluR7, and GABAB1 antibodies recognized bands of ∼55, 60, 57, 140, 132, 100,
and 190, 97, 100, and 132 kDa in the order in crude membrane fractions of rat cerebral cortex.
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FIGURE 2 | Expression of metabotropic glutamate and GABA receptors in cerebral cortex. The figure shows representative images from the VGLUT1 series
(first row), the VGLUT2 series (second row), and the VGAT series (third row). Puncta were considered double-labeled (arrows) when overlap was virtually complete or
when a given punctum was entirely included in the other puncta. Bar: 4 μm.
acid (LY367385, ab120067), (1R,4R,5S,6R)-4-amino-2-
oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268,
ab120196), (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]
-3-(xanth-9-yl)propanoic acid (LY341495, ab120199), N,N’-
Dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082
dihydrochloride, ab120011), 6-(4-Methoxyphenyl)-5-methyl-
3-(4-pyridinyl)isoxazolo[4,5-c]pyridin-4(5H)-one (MMPIP,
ab120245) were from ABCAM (Cambridge, UK).(R)-4-Amino-
3-(4-chlorophenyl)butanoic acid ((-)baclofen, code 0796) and 3-
[[(3,4-Dichlorophenyl)methyl]amino]propyl] diethoxymethyl)
phosphinic acid (CGP 52432, code 1246) were from Tocris
Bioscience (Bristol, UK).
Statistical Analysis
Statistical signiﬁcance was evaluated by non-parametric Mann–
Whitney U test (for confocal microscopy in cerebellum and
ventrobasal complex), and non-parametric one way ANOVA
(Kruskal–Wallis with Dunn’s post-test for confocal microscopy
and release experiments in cerebral cortex).
Results
In cortical crude membrane fractions, all antibodies recognized
bands of the predicted molecular mass (Figure 1; Reid et al.,
1995; Petralia et al., 1996; Bellocchio et al., 1998; Chaudhry
et al., 1998; Kinoshita et al., 1998; Kulik et al., 2002; Varoqui
et al., 2002). VGLUT1, VGLUT2,mGluR1α, mGluR5, mGluR2/3,
mGluR7, and GABAB1 immunoreactivities were as described
in previous studies (Reid et al., 1995; Romano et al., 1995;
Petralia et al., 1996; Bellocchio et al., 1998; Chaudhry et al.,
1998; Kinoshita et al., 1998; Kaneko et al., 2002; Kulik et al.,
2002; Lopez-Bendito et al., 2002; Minelli et al., 2003; Muly
et al., 2003; Alonso-Nanclares et al., 2004; Conti et al.,
2005). These antibodies were, therefore, used to verify whether
mGluR1α, mGluR5, mGluR2/3, mGluR7, and GABAB1 are
diﬀerentially expressed in VGLUT1+, VGLUT2+, and VGAT+
axon terminals.
Expression of mGluRs and GABAB1 in VGLUT1+ cortical
axon terminals was studied in 25 sections from eight rats
(Figures 2 and 3).
The results showed that 4.93% of VGLUT1+ puncta expressed
mGluR1α, 6.31% mGluR5, 22.01% mGluR2/3, 17.23% mGluR7,
and 39.59% GABAB1 (Figure 3; Table 2). Analysis of VGLUT2+
cortical axon terminals (30 sections from 10 animals) showed
that 9.74% of VGLUT2+ puncta co-localized mGluR1α, 10.55%
mGluR5, 20.37% mGluR2/3, 28.03% mGluR7, and 24.79%
GABAB1 (Figure 3; Table 2). Analogous studies of VGAT+
puncta (24 sections from 8 rats) revealed that 27.18% of VGAT
expressedmGluR1α, 24.20%mGluR5, 38.09%mGluR2/3, 31.39%
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mGluR7, and 18.94% GABAB1 (Figure 3; Table 2). None of
the proteins studied exhibited a signiﬁcant diﬀerential laminar
distribution.
Since mGluRs and GABAB are located both pre- and
postsynaptically, we tested whether our data on pre-synaptic
localization had been biased by the presence of postsynaptic
receptors. GABAB1 is expressed presynaptically in cerebellum
but not in the thalamic ventrobasal complex (Kulik et al.,
2002); we therefore studied GABAB1 expression in VGLUT1,
VGLUT2, and VGAT+ puncta in cerebellum and ventrobasal
complex (2 rats, 12 sections) to verify whether our confocal
method was able to diﬀerentiate pre-synaptic from postsynaptic
localization. We found that whereas in cerebellum 19 ± 1% of
VGLUT1, 9.6± 0.3% of VGLUT2, and 9.2 ± 0.3% of VGATwere
FIGURE 3 | Expression of mGluR1α, mGluR5, mGluR2/3, mGluR7, and
GABAB1 in VGLUT1+, VGLUT2+, and VGAT+ axon terminals in
cerebral cortex. Values are mean ± SEM; ∗∗p < 0.01, ∗∗∗p < 0.001.
TABLE 2 | mGluR1α, mGluR5, mGluR2/3, mGluR7, and GABAB1 in VGLUT1,
VGLUT2, and VGAT puncta.
VT Puncta (#) Co-localization MR
VGLUT1 3841 4.93 ± 0.95% mGluR1α
5058 6.31 ± 0.26% mGluR5
3276 22.01 ± 0.95% mGluR2/3
3925 17.23 ± 0.22% mGluR7
3927 39.59 ± 3.39% GABAB1
VGLUT2 3235 9.74 ± 0.43% mGluR1α
4444 10.55 ± 0.06% mGluR5
6424 20.37 ± 1.36% mGluR2/3
3925 28.04 ± 1.57% mGluR7
3363 24.79 ± 4.54% GABAB1
VGAT 2942 27.18 ± 0.41% mGluR1α
2675 24.2 ± 1.40% mGluR5
2732 38.09 ± 2.13% mGluR2/3
2615 31.39 ± 1.60% mGluR7
2245 18.94 ± 0.75% GABAB1
VT, vesicular transporter; MR, metabotropic receptor.
GABAB1+, in ventrobasal complex only 4.9± 0.1%, of VGLUT1,
4.4± 0.1% of VGLUT2, and 4.2± 0.2% of VGATwere GABAB1+
(Figure 4). These ﬁndings indicate that most of labeling identiﬁed
as presynaptic is indeed presynaptic, even though values given
in the preceding paragraph may be slightly overestimated (see
Discussion).
To further conﬁrm the presynaptic localization of mGluRs
and GABAB1 and to gain insights on their functional role,
we studied the impact of activation of the two classes of
metabotropic receptors on the release of endogenous glutamate
andGABA in rat parietal cortex. The spontaneous eﬄux of GABA
and Glu from cerebral cortex synaptosomes in superfusion,
in the absence of stimulus amounted to 51.4 ± 4.62 and to
99.6 ± 4.95 pmol/mg of proteins, respectively. The 15 mM
FIGURE 4 | Control analysis of confocal microscopy images. VGLUT1/GABAB1 in molecular layer of cerebellum (Cb) and in ventrobasal complex (VB). Puncta
were considered double-labeled when overlap was virtually complete or when a given punctum was entirely included in the other puncta (arrows in third and fourth
columns). Puncta that did not meet these criteria (arrowheads) were not considered double-labeled; Bars: 2 μm.
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KCl-evoked GABA and Glu overﬂow amounted to 215.83 ± 17
and to 482.15 ± 38.2 pmol/mg of proteins, respectively. 3,5-
DHPG (30 μM), an agonist of mGluR1/5 (Wisniewski and Car,
2002), increased the spontaneous outﬂow of Glu from rat parietal
cortex synaptosomes in superfusion by 40.26 ± 7.45%; its eﬀect
was counteracted by the mGluR1 antagonist LY367385 (1 μM;
Bruno et al., 1999) and the mGluR5 antagonist MPEP (1 μM;
Gasparini et al., 1999; Figure 5). Similar results were obtained
by measuring the potentiation by DHPG (41.60 ± 7.65%) and
the antagonism by LY367385 and MPEP on the basal release
of GABA (Figure 5). LY379268 (0.1 μM), a selective mGluR2/3
agonist (Monn et al., 1999), signiﬁcantly reduced the 15 mM
KCl-evoked overﬂow of Glu (by 40.23 ± 5.2%; Figure 5) and
of GABA (by 30 ± 6%; Figure 5); both eﬀects were reverted by
0.01 μM LY341495, a selective mGluR2/3 antagonist (Kingston
et al., 1998). AMN082 (0.1 μM), a selective mGluR7 agonist
(Mitsukawa et al., 2005), inhibited the release of Glu (by
39.08 ± 3.07%; (Figure 5) and GABA (35.3 ± 6.45%; (Figure 5)
induced by 15 mM KCl; both eﬀects were reverted by 0.01 μM
MMPIP, a selective mGluR7 antagonist (Suzuki et al., 2007).
Next, we analyzed the eﬀect of (-)baclofen, a selective GABAB
receptor agonist (Bowery et al., 1980), on the release of glutamate
and GABA induced by 15 mM KCl. Figure 5 shows that the
release of glutamate induced by depolarization was signiﬁcantly
reduced (by 49.37 ± 3.39%) by 10 μM(-)baclofen. The eﬀect
of (-)baclofen was reverted by the selective GABAB receptor
antagonist CGP52432 (1 μM) (Froestl et al., 1995). (-)baclofen
(10 μM) also inhibited the 15 mM KCl-evoked release of GABA
(reducing it by 40.79± 8.12%), and its eﬀect was counteracted by
1 μM CGP52432 (Figure 5). These studies conﬁrm and extend
the results of previous studies, by showing that presynaptic
mGluRs modulate and GABAB reduces Glu and GABA release
and that the eﬀects on the release of the two amino acid were
comparable.
Discussion
The present study showed that mGluRs and GABAB receptors
are diﬀerentially expressed in glutamatergic and GABAergic
axon terminals. Interestingly, mGluR1α, mGluR5, mGluR2/3,
and mGluR7 are more robustly expressed at GABAergic than at
glutamatergic terminals, whereas GABAB1 is more expressed in
glutamatergic terminals. In addition, we showed that in cerebral
cortex mGluR1 and mGluR5 potentiate Glu and GABA release,
whereas mGluR2/3, mGluR7, and GABAB receptors inhibit it.
As reported in Introduction, the mGluRs studied in the
present investigation have a presynaptic localization. Indeed,
besides mGluR2/3 – a paradigmatic presynaptic mGluR (Ohishi
et al., 1994; Neki et al., 1996; Petralia et al., 1996; Lujan et al.,
1997; Tamaru et al., 2001), presynaptic expression of mGluR1α,
mGluR5 (which aremostly postsynaptic) andmGluR7 in cerebral
cortex has been documented (Romano et al., 1995; Bradley
et al., 1996; Shigemoto et al., 1996, 1997; Kinzie et al., 1997;
Kinoshita et al., 1998; Kosinski et al., 1999; Dalezios et al.,
2002; Muly et al., 2003; Somogyi et al., 2003). However, some
of the mGluRs studied and GABAB receptors are expressed
FIGURE 5 | Effect of agonists and antagonists of mGluR1/5, mGluR2/3,
mGluR7, or GABAB receptors on the release of endogenous glutamate
(A) and GABA (B) from rat parietal cortex synaptosomes. Data are
expressed as percent of the spontaneous outflow (mGluR1/5 effect) or of the
15 mM KCl-evoked overflow (mGluR2/3/7 and GABAB effects). White and
gray columns refer to agonist or agonist + antagonist administration. Data are
means ± SEM of 6–10 independent experiments (6–10 rats per group).
∗p < 0.05 and ∗∗p < 0.01 vs. controls.
both pre- and postsynaptically (Kulik et al., 2002; Lopez-
Bendito et al., 2002; Boyes and Bolam, 2003; Kulik et al.,
2003; Chen et al., 2004; Lujan et al., 2004; Lacey et al.,
2005; Lujan and Shigemoto, 2006). Therefore, we performed
several control studies to rule out the possibility that our
“presynaptic” population had been contaminated by postsynaptic
receptors. Since presynaptic localization of GABAB1 occurs in
cerebellum but not in the thalamic ventrobasal (VB) nucleus
(Kulik et al., 2002), we ﬁrst studied the co-localization of
GABAB1 receptor and VGLUT1, VGLUT2, and VGAT in both
cerebellum and VB, and found a signiﬁcant diﬀerences between
co-localization in cerebellum and VB (where co-localization
was very low) in the three types of terminals. It is therefore
safe to assume that our confocal method can satisfactorily
discriminate presynaptic and postsynaptic expression. This view
is further reinforced by the observation that in our experimental
conditions GABAB1 agonists elicited modulatory responses.
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Next, we performed functional assays in synaptosomal
preparations, which provided further evidence that the mGluRs
and GABAB studied immunocytochemically are indeed located
presynaptically. To this purpose, we monitored Glu and GABA
release in cerebral cortex synaptosomes under superfusion
conditions (Raiteri et al., 1984). It has been demonstrated
that by this way all the released transmitters/modulators are
immediately removed by the superfusion medium ﬂow, before
they can interact with receptors or other proteins expressed at
the presynaptic level. As a consequence, any drug-induced eﬀect
on the release of a given neurotransmitter can be attributed
exclusively to the direct action of the drug at the nerve
terminal storing and releasing that neurotransmitter. Thus, the
modulation of Glu or GABA release reported here is in all
likelihood due to activation of mGluRs or GABAB1 receptors
located at Glu or GABA releasing nerve terminals, respectively.
Overall, these sets of data provide evidence that, although
we might have slightly (<5%) overestimated the population
of mGluRs and GABAB receptors, our immunocytochemical
localization of presynaptic receptors was not grossly biased
by their postsynaptic localization. The present observation
that in adult neocortex mGlu and GABAB1 receptors exhibit
diﬀerences between glutamatergic and GABAergic terminals
expands the notion that these axon terminals greatly diﬀer in
their complement of presynaptic proteins (Bragina et al., 2007,
2010, 2011).
The present results show that not all glutamatergic terminals
express mGluRs. Indeed, our data indicate that at least 60% of
VGLUT1+ and >10% of VGLUT2+ glutamatergic terminals are
devoid of glutamate-mediated metabotropic control. Moreover,
these percentages could be signiﬁcantly increased by the
possibility that some terminals express more than one mGluR. As
far as VGAT+ terminals are concerned, the present data suggest
that all of them could express mGluRs, although the lack of
triple-labeling studies prevent a ﬁrm conclusion, and that only a
small fraction do exhibit GABA-mediated metabotropic control.
Thus, although the amount of data available is still limited, it
is safe to conclude that not all glutamatergic and GABAergic
terminals are controlled through metabotropic receptors by
glutamate and GABA, respectively.
Besides this, our results provide some novel data on mGluRs
andGABAB receptors localization in cerebral cortex. mGluRs and
GABAB receptors have been described in both glutamatergic
and GABAergic terminals (Gereau and Swanson, 2008; Raiteri,
2008, for reviews), but the present quantitative observation in
neocortex that presynaptic mGluRs are so strongly expressed
in GABAergic and that presynaptic GABAB receptors are more
expressed in glutamatergic than in GABAergic terminals adds
much to previous observations and opens a new perspective
to unravel cortical microcircuits. Indeed, although the complex
relationships between glutamatergic and GABAergic are only
beginning to be unveiled (Lujan et al., 2005; Pinheiro and
Mulle, 2008; Heja et al., 2009), making any hypothesis
fragile, it is conceivable that the strong heterolocalization of
mGluRs and GABAB receptors at cortical axon terminals is part
of the complex homeostatic mechanism regulating the balance
between excitation and inhibition.
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